Biogen Idec, Inc. (BIIB) Tops Q3 Adj-EPS by 8c
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q3 EPS of $1.61, ex-items, $0.08 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.27 billion.